Cargando…

Standardized neutralization antibody analytical procedure for clinical samples based on the AQbD concept

Detalles Bibliográficos
Autores principales:	Liu, Jianyang, Bai, Yu, Liu, Mingchen, Tan, Dejiang, Li, Jing, Wang, Zhongfang, Liang, Zhenglun, Xu, Miao, Wang, Junzhi, Mao, Qunying
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10140029/ https://www.ncbi.nlm.nih.gov/pubmed/37105999 http://dx.doi.org/10.1038/s41392-023-01389-5

Ejemplares similares

Analytical Quality by Design (AQbD) Approach to the Development of Analytical Procedures for Medicinal Plants
por: Park, Geonha, et al.
Publicado: (2022)

Development of a Stability-Indicating Analytical Method for Determination of Venetoclax Using AQbD Principles
por: Žigart, Nina, et al.
Publicado: (2020)

Analytical Quality by Design (AQbD) Approach to the Development of In Vitro Release Test for Topical Hydrogel
por: Szoleczky, Réka, et al.
Publicado: (2022)

Establishment of national standard for anti-SARS-Cov-2 neutralizing antibody in China: The first National Standard calibration traceability to the WHO International Standard
por: Guan, Lidong, et al.
Publicado: (2023)

A Systematic AQbD Approach for Optimization of the Most Influential Experimental Parameters on Analysis of Fish Spoilage-Related Volatile Amines
por: Freitas, Jorge, et al.
Publicado: (2020)

Development and Validation of a Stability-Indicating UPLC Method for the Determination of Hexoprenaline in Injectable Dosage Form Using AQbD Principles
por: Afonso Urich, Jesús Alberto, et al.
Publicado: (2021)

AQbD based green UPLC method to determine mycophenolate mofetil impurities and Identification of degradation products by QToF LCMS
por: Muchakayala, Siva Krishna, et al.
Publicado: (2022)

Establishment of the 1st Chinese national standard for CA6 neutralizing antibody
por: Wang, Yiping, et al.
Publicado: (2023)

Considerations for the Feasibility of Neutralizing Antibodies as a Surrogate Endpoint for COVID-19 Vaccines
por: Liu, Jianyang, et al.
Publicado: (2022)

Development and Validation of an in-line API Quantification Method Using AQbD Principles Based on UV-Vis Spectroscopy to Monitor and Optimise Continuous Hot Melt Extrusion Process
por: Almeida, Juan, et al.
Publicado: (2020)

Mixed formulation of mRNA and protein‐based COVID‐19 vaccines triggered superior neutralizing antibody responses
por: Zhang, Jialu, et al.
Publicado: (2022)

Development of an ELISA Assay for the Determination of SARS-CoV-2 Protein Subunit Vaccine Antigen Content
por: Han, Lu, et al.
Publicado: (2022)

Heterologous Omicron-adapted vaccine as a secondary booster promotes neutralizing antibodies against Omicron and its sub-lineages in mice
por: Liu, Jianyang, et al.
Publicado: (2022)

B.1.351 SARS-CoV-2 Variant Exhibits Higher Virulence but Less Viral Shedding than That of the Ancestral Strain in Young Nonhuman Primates
por: Bai, Yu, et al.
Publicado: (2022)

Amplifying mRNA vaccines: potential versatile magicians for oncotherapy
por: Hu, Chaoying, et al.
Publicado: (2023)

Regulatory science accelerates the development of biotechnology drugs and vaccines by NIFDC
por: Liang, Zhenglun, et al.
Publicado: (2014)

Research progress on circular RNA vaccines
por: Bai, Yu, et al.
Publicado: (2023)

Bumetanide-Derived Aquaporin 1 Inhibitors, AqB013 and AqB050 Inhibit Tube Formation of Endothelial Cells through Induction of Apoptosis and Impaired Migration In Vitro
por: Tomita, Yoko, et al.
Publicado: (2019)

COVID-19 Vaccines: Current Understanding on Immunogenicity, Safety, and Further Considerations
por: He, Qian, et al.
Publicado: (2021)

Effective protection of ZF2001 against the SARS-CoV-2 Delta variant in lethal K18-hACE2 mice
por: Bian, Lianlian, et al.
Publicado: (2022)

The Cross-Neutralizing Activity of Enterovirus 71 Subgenotype C4 Vaccines in Healthy Chinese Infants and Children
por: Mao, Qunying, et al.
Publicado: (2013)

COVID-19 vaccines: progress and understanding on quality control and evaluation
por: Mao, Qunying, et al.
Publicado: (2021)

Research progress on vaccine efficacy against SARS-CoV-2 variants of concern
por: Bian, Lianlian, et al.
Publicado: (2022)

Heterologous prime-boost: breaking the protective immune response bottleneck of COVID-19 vaccine candidates
por: He, Qian, et al.
Publicado: (2021)

Development of a pseudovirus based assay for measuring neutralizing antibodies against coxsackievirus B5
por: Chen, Pan, et al.
Publicado: (2017)

Development and Evaluation of a Pseudovirus-Luciferase Assay for Rapid and Quantitative Detection of Neutralizing Antibodies against Enterovirus 71
por: Wu, Xing, et al.
Publicado: (2013)

Comparing the Primary and Recall Immune Response Induced by a New EV71 Vaccine Using Systems Biology Approaches
por: Shao, Jie, et al.
Publicado: (2015)

A rapid and quantitative assay for measuring neutralizing antibodies of Coxsackievirus B3
por: Chen, Pan, et al.
Publicado: (2016)

EV-A71 vaccine licensure: a first step for multivalent enterovirus vaccine to control HFMD and other severe diseases
por: Mao, Qunying, et al.
Publicado: (2016)

Application of the Analytical Procedure Lifecycle Concept to a Quantitative (1)H NMR Method for Total Dammarane-Type Saponins
por: Li, Wenzhu, et al.
Publicado: (2023)

Transcriptomic analysis of the innate immune signatures of a SARS-CoV-2 protein subunit vaccine ZF2001 and an mRNA vaccine RRV
por: Wang, Qian, et al.
Publicado: (2022)

EV71 vaccine, an invaluable gift for children
por: Liang, Zhenglun, et al.
Publicado: (2014)

Research Advances on the Stability of mRNA Vaccines
por: Cheng, Feiran, et al.
Publicado: (2023)

Non-neutralizing monoclonal antibody targeting VP2 EF loop of Coxsackievirus A16 can protect mice from lethal attack via Fc-dependent effector mechanism
por: Du, Ruixiao, et al.
Publicado: (2022)

Evaluation of the cross-neutralization activities elicited by Coxsackievirus A10 vaccine strains
por: Huo, Yaqian, et al.
Publicado: (2021)

Heterologous immunization with adenovirus vectored and inactivated vaccines effectively protects against SARS-CoV-2 variants in mice and macaques
por: He, Qian, et al.
Publicado: (2022)

A Novel Single-Stranded RNA-Based Adjuvant Improves the Immunogenicity of the SARS-CoV-2 Recombinant Protein Vaccine
por: Liu, Dong, et al.
Publicado: (2022)

A Novel Targeted RIG-I Receptor 5′Triphosphate Double Strain RNA-Based Adjuvant Significantly Improves the Immunogenicity of the SARS-CoV-2 Delta-Omicron Chimeric RBD-Dimer Recombinant Protein Vaccine
por: Bai, Yu, et al.
Publicado: (2023)

Comparative Analysis of the Immunogenicity and Protective Effects of Inactivated EV71 Vaccines in Mice
por: Mao, Qunying, et al.
Publicado: (2012)

Effects of SARS-CoV-2 variants on vaccine efficacy and response strategies
por: Bian, Lianlian, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_oa9cejth7bptqcpmjhmgoj76fi